Evidence map›Paper›PMID 35831895›Full record

ArticleBiology direct2022

A functional reference map of the RNF8 interactome in cancer.

Chuanyang Liu, Jingyu Kuang, Yuxuan Wang, Ting Duan, Lu Min, Chenyu Lu, Tianyi Zhang, Ruifen Chen, Ying Wu, Lingyun Zhu

Open access · goldAbstract read
In one paragraph

Article in Biology direct, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer.International journal of molecular sciences · 2023
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Chuanyang Liu *Department of Biology and Chemistry, College of Sciences, National University of Defense Technology, Changsha, 410073, Hunan, China.
Jingyu Kuang *Department of Biology and Chemistry, College of Sciences, National University of Defense Technology, Changsha, 410073, Hunan, China. kuangkuangyu@126.com.
Yuxuan WangDepartment of Biology and Chemistry, College of Sciences, National University of Defense Technology, Changsha, 410073, Hunan, China.
Ting DuanKey Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
Lu MinDepartment of Biology and Chemistry, College of Sciences, National University of Defense Technology, Changsha, 410073, Hunan, China.
Chenyu LuDepartment of Biology and Chemistry, College of Sciences, National University of Defense Technology, Changsha, 410073, Hunan, China.
Tianyi ZhangDepartment of Biology and Chemistry, College of Sciences, National University of Defense Technology, Changsha, 410073, Hunan, China.
Ruifen ChenJoint Logistic Support Force 921th Hospital, Changsha, 410073, Hunan, China.
Ying WuDepartment of Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Lingyun ZhuDepartment of Biology and Chemistry, College of Sciences, National University of Defense Technology, Changsha, 410073, Hunan, China. lingyunzhu@nudt.edu.cn.
National University of Defense Technology · CNCentral South University · CNHangzhou Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRNF8 is an E3 ligase identified as a critical DNA damage-responsive protein. Recently, multiple reports have shown that RNF8 could be used as an important therapeutic target for cancer chemo/radiotherapy. However, the understanding of RNF8 remains limited due to the lack of its interactome reference map and comprehensive analysis of RNF8 in diverse cancers, which underscores the need to map the interactome of RNF8 via high-throughput methods.

resultsA two-way identification method based on LC-MS was designed for the identification of the RNF8 interactome with high-specificity. By in silico analysis and in vitro validation, we identified a new reference map of the RNF8 interactome network containing many new targets, such as YBX1, DNMT1, and HDCA1, new biological functions and the gene-disease associations of RNF8. Our results revealed a close relationship between RNF8 and neurodegenerative diseases or tumor-infiltrating immune cells using bulk RNA-seq and scRNA-seq datasets. As a proof of concept of our interactome map, we validated the direct binding between RNF8 and YBX1 and showed that RNF8 catalyzed the ubiquitination of YBX1. These results demonstrated that RNF8 might be a crucial regulator of YBX1.

conclusionsOur work provides a unique framework for researchers and clinicians who seek to better explore or understand RNF8-regulated biological functions in cancers. This study will hopefully facilitate the rational design and further development of anti-RNF8 therapy in cancers.

Indexed as

DNA-Binding ProteinsNeoplasmsDNA DamageHumansUbiquitinationUbiquitin-Protein LigasesDNA-Binding ProteinsRNF8 protein, humanUbiquitin-Protein LigasesInteractomePancancer analysisRNF8UbiquitinationYBX1

Identifiers

PMID35831895
PMCPMC9277853
OpenAlexW4285083284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.